BRISTOL-MYERS Aktie

 

As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential....

The exercise is simple: how large a position in Bristol Myers Squibb (NYSE:BMY) do you need to throw off $10,000 a year in dividend income? Start with the income target and solve backward, using the live yield and the live payout. That is the only way the number means anything. Bristol Myers Squibb is a […]...

Massacesi, Cristian - Vorstand - Tag der Transaktion: 2026-09-09...

Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close....

Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution....

NORTHAMPTON, MA / ACCESS Newswire / September 9, 2026 / Organizations Across Sectors Unite Through the Winn Awards to Advance Better Science For All Previously published by the Robert A. Winn Excel......

Bristol Myers Squibb and seasoned biotechnology veteran Donald Hayden, M.B.A., appointed as Chairman of the Latus Board of Directors Former Chief Financial Officer of Avidity Biosciences Michael MacLean appointed as independent director and Chair of the Audit Committee Appointments come as Latus advances its lead programs into clinical trials, including LTS-101 for CLN2 disease and LTS-201 for Huntington's diseasePHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the appointments of Donald Hayden, M.B.A., as Chairman and Michael MacLean as independent director and Chair of the Audit Committee of the Latus Board of Directors. Mr. Hayden and Mr. MacLean bring decades of executive leadership experience in driving successful biopharmaceutical companies through key value inflection points and delivering advanced medicines for rare disease patients with high unmet needs. Their appointments come as Latus transitions into ...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Former Bristol Myers Squibb executive Samuel Moed and Compugen chairperson Dr. Anat Cohen-Dayag are leading the Israel National Biotech Innovation Center....

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day....

Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion....

Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky....

Program yields evidence supporting $14.1 million in savings by keeping patients out of the hospital ALEXANDRIA, VA / ACCESS Newswire / September 3, 2026 / Originally published on NCPA.orgA trailbla......

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force....

BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs....

Holzer, Phil M. - Vorstand - Tag der Transaktion: 2026-08-25...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Aug. 24, 2026 /PRNewswire/ -- BRC Therapeutics (BRC), a clinical-stage pharmaceutical......

BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook....

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third....